Wells Fargo & Company Upgrades Sutro Biopharma (NASDAQ:STRO) to “Overweight”

Sutro Biopharma (NASDAQ:STRO) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating in a research report issued on Tuesday, Marketbeat.com reports. The firm presently has a $27.00 price objective on the stock, up from their previous price objective of $8.00. Wells Fargo & Company‘s price target points to a potential upside of 14.89% from the company’s current price.

Several other research firms have also commented on STRO. Wedbush reissued a “neutral” rating and issued a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Finally, HC Wainwright upgraded shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $10.00 to $28.00 in a research note on Tuesday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $37.29.

Sutro Biopharma Price Performance

Shares of Sutro Biopharma stock opened at $23.50 on Tuesday. The stock has a market capitalization of $199.99 million, a price-to-earnings ratio of -0.90 and a beta of 1.47. The business has a 50-day moving average of $18.61 and a 200 day moving average of $12.76. Sutro Biopharma has a 12 month low of $5.23 and a 12 month high of $26.54.

Institutional Trading of Sutro Biopharma

A number of large investors have recently made changes to their positions in STRO. GSA Capital Partners LLP purchased a new position in Sutro Biopharma in the third quarter worth approximately $152,000. Velan Capital Investment Management LP increased its position in shares of Sutro Biopharma by 197.1% in the 2nd quarter. Velan Capital Investment Management LP now owns 3,060,000 shares of the company’s stock valued at $2,185,000 after purchasing an additional 2,030,000 shares during the last quarter. RBF Capital LLC acquired a new stake in shares of Sutro Biopharma in the 2nd quarter valued at $114,000. Invesco Ltd. raised its holdings in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Sutro Biopharma during the 4th quarter worth $265,000. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Sutro Biopharma News Summary

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55 (from $51) and kept a Buy rating — a materially higher target that suggests strong upside vs. the current share price and supports bullish investor expectations. Deutsche Bank raises PT to $55
• Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and raised its price target to $27 (from $8), signaling improving institutional sentiment and providing a nearer-term upside anchor for the stock. Wells Fargo upgrade
• Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its target to $28 (from $10). The firm also published FY2030 EPS projections (large negative EPS expected), but maintained a Buy stance and higher target — a supportive signal from a biotech-focused shop. HC Wainwright upgrade HC Wainwright EPS note
• Neutral Sentiment: Short-interest reports for March show anomalous values (reported as 0 shares with NaN changes and 0.0 days-to-cover across different volume baselines). The data appears unreliable or reflects a reporting/clearing event, so its immediate impact on price is unclear. (Multiple internal short-interest notices consolidated)

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.